Home > Insider Trading > Filing (0001209191-23-052030)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
827871	Eagle Pharmaceuticals Inc.	EGRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1469124	Scott Tarriff	C/O Eagle Pharmaceuticals, Inc. 50 Tice Blvd., Suite 315 Woodcliff Lake NJ 07677	Ceo	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-10-02	9,511	$15.23	577,800	No	4	S	Direct
Common Stock	Disposition	2023-10-03	10,024	$14.41	567,776	No	4	S	Direct
Common Stock	Disposition	2023-10-03	710	$15.11	567,066	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	992,623	Indirect	By Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016

Footnotes

These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.035 to $15.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.09 to $15.05 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.18 inclusive.
The shares are held by the Trust for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.